Prognostic role of liver X receptor‐alpha in resected stage II and III non‐small‐cell lung cancer

Melloni, Giulio; Muriana, Piergiorgio; Bandiera, Alessandro; Fontana, Raffaella; Maggioni, Daniela; Russo, Vincenzo; Doglioni, Claudio; Zannini, Piero

doi:10.1111/crj.12522

Cited by 13 publications

(10 citation statements)

References 15 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the clinical and pathological features, there were 28 patients with lymph node metastasis (N1) and 17 patients without lymph node metastasis (N0). TNM staging is based on the TNM staging criteria for non-small cell lung cancer (2003 Edition) established by the American Joint Committee on Cancer (AJCC) (21). According to this criterion, there were 10 cases of stage I, 16 cases of stage II, 10 cases of stage III and 9 cases of stage IV.…”

Section: Methodsmentioning

confidence: 99%

miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1

Fang

Pan

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

The present study determined the role and mechanism of miR-138 in non-small cell lung cancer (NSCLC). In total, 45 freshly resected clinical NSCLC tissues were collected. The expression of miR-138 in tissues and cell lines were determined by real-time quantitative PCR. miR-138 mimics were transfected into A549 and Calu-3 cells in vitro, and then the effects of miR-138 on lung cancer cell proliferation, cell cycle, invasion and metastasis were investigated by CCK-8 assay, Transwell and flow cytometry, respectively. The protein expression of the potential target gene Sirt1 in lung cancer cells were determined by western blot analysis. Dual-Luciferase reporter assay was performed to further confirm whether Sirt1 was the target gene of miR-138. The expression of miR-138 was significantly lower in lung cancer tissues and was negatively correlated to the differentiation degree and lymph node metastasis of lung cancer. In vitro experiment results showed that miR-138 inhibited lung cancer cell proliferation, invasion and migration. It was verified that miR-138 could downregulate Sirt1 protein expression, inhibit epithelial-mesenchymal transition (EMT), decrease the activity of AMPK signaling pathway and elevate mTOR phosphorylation level. Dual-Luciferase reporter assay demonstrated that miR-138 could directly regulate Sirt1. Downregulation of Sirt1 alone can also cause the same molecular and biological function changes. Western blot analysis and confocal microscopy results indicated that overexpression of miR-138 or interference of Sirt1 expression could inhibit lung cancer cell autophagy activity possibly through AMPK-mTOR signaling pathway. miR-138 plays a tumor suppressor function in lung cancer. It may inhibit the proliferation, invasion and migration of lung cancer through downregulation of Sirt1 expression and activation of cell autophagy. The downregulation of miR-138 is closely related to the development of lung cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1

Fang

Pan

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…They are intimately related nuclear receptors that react to elevated levels of intracellular cholesterol by enhancing transcription of genes that control cholesterol efflux and FA biosynthesis. NR1H3 expression was significantly correlated to better survival in completely resected stages II and III NSCLC patients (164). Moreover, one study reports that NR1H3 and NR1H2 belong to a transcription signature associated with poor CRC clinical outcome independent of lymph node metastasis, distant metastasis, and advanced stage (156).…”

Section: Lipid-related Transcription Factor Alterations As Biomarkersmentioning

confidence: 99%

Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment

2020

View full text Add to dashboard Cite

“…Although advances have been made in multidisciplinary treatments for lung cancer, this cancer continues to have a poor prognosis due to a general lack of symptoms until it reaches an advanced stage ( 7 ). Due to discrepancies between results within the same stage, there is an urgent demand for novel parameters, particularly serum predictive biomarkers, to combine with low-dose computed tomography, x-ray examination and other diagnostic tests to complement tumor-node-metastasis (TNM) staging ( 8 ) to accurately predict the prognosis and provide appropriate preoperative patient counseling ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer

Wang

Liang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

As the leading cause of cancer-associated mortality globally among males in 2012, lung cancer is a disease of particular concern. Previously, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) were revealed to be prognostic factors for various types of cancer, including lung cancer. In the present study, a retrospective review was conducted with patients who were diagnosed with lung cancer between January 1, 2000 and December 31, 2005 in the Fourth Hospital of Hebei Medical University. A total of 695 patients were included, and the optimal cutoffs of the NLR and the PLR were 6.0 and 248.0, respectively. There were statistically significant associations between tumor-node-metastasis (TNM) stage, surgery, metastasis incidence and NLR (P<0.001). The associations between TNM stage, surgery incidence and PLR were also revealed to be statistically significant (P<0.001). Patients in the low NLR group demonstrated longer overall survival (OS) than patients in the high NLR group (819.57 days vs. 629.86 days, P=0.041). The NLR at diagnosis was demonstrated to be an independent prognostic factor for OS. Thus, the NLR may be a promising approach for predicting the prognosis of patients with lung cancer.

show abstract

Prognostic role of liver X receptor‐alpha in resected stage II and III non‐small‐cell lung cancer

Abstract: LXR-alpha seems to be an independent prognostic factor indicating a better survival in completely resected stage II and III NSCLC patients.

Cited by 13 publications

References 15 publications

miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1

miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1

Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment

The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer

Contact Info

Product

Resources

About